Yiu ZZN, Mason KJ, Hampton PJ, et al. - Researchers conducted this prospective cohort study to evaluate the relative drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis and to examine predictors of biologic drug survival. This investigation was carried out in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) between November 2007 and August 2019. Participants in the study were 9,652 patients [5,543 starting on adalimumab (57·4%), 991 on secukinumab (10·3%) and 3,118 on ustekinumab (32·3%)]. Data reported that the overall drug survivals of adalimumab, secukinumab and ustekinumab in year 1, respectively, were 0·78, 0·88 and 0·88. Secukinumab and ustekinumab have similarly sustained drug survival whereas in patients with psoriasis, adalimumab has lower drug survival. Psoriatic arthritis and previous biologic experience have been predictors of differential effects between biologic therapies.